The reinstatement of Immunocore Holdings by JP Morgan with an Overweight rating and a high price target suggests a strong bullish sentiment from the analyst. This could lead to increased investor confidence and a potential rise in the stock price in the short term, as market participants often react positively to such analyst upgrades and price target announcements.